Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Change in Cash (2021 - 2025)

Historic Change in Cash for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $23.3 million.

  • Aligos Therapeutics' Change in Cash rose 33987.84% to $23.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 11886.66%. This contributed to the annual value of -$98.7 million for FY2024, which is 28166.7% down from last year.
  • Latest data reveals that Aligos Therapeutics reported Change in Cash of $23.3 million as of Q3 2025, which was up 33987.84% from -$55.1 million recorded in Q2 2025.
  • In the past 5 years, Aligos Therapeutics' Change in Cash registered a high of $65.3 million during Q4 2023, and its lowest value of -$111.4 million during Q1 2024.
  • Over the past 5 years, Aligos Therapeutics' median Change in Cash value was -$5.1 million (recorded in 2022), while the average stood at -$9.4 million.
  • Per our database at Business Quant, Aligos Therapeutics' Change in Cash soared by 139045.08% in 2023 and then tumbled by 455164.93% in 2024.
  • Quarter analysis of 5 years shows Aligos Therapeutics' Change in Cash stood at -$53.4 million in 2021, then skyrocketed by 90.53% to -$5.1 million in 2022, then soared by 1390.45% to $65.3 million in 2023, then tumbled by 97.45% to $1.7 million in 2024, then soared by 1297.66% to $23.3 million in 2025.
  • Its Change in Cash stands at $23.3 million for Q3 2025, versus -$55.1 million for Q2 2025 and $36.8 million for Q1 2025.